Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.33 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1556224 | 0.97 | DAO (0.35) | DAOHDAC8HDAC6AURKAAURKB | |
| SCHEMBL28372504 | 0.87 | NAPRT (0.31) | DAOHDAC8HDAC6AURKAAURKB | |
| SCHEMBL1557675 | 0.79 | CYP3A4 (0.50) | FKBP5NAPRT | |
| SCHEMBL1557189 | 0.79 | CYP3A4 (0.50) | FKBP5NAPRT | |
| SCHEMBL4711517 | 0.74 | AURKA (0.37) | DAOHDAC8HDAC6AURKAAURKB | |
| SCHEMBL31512727 | 0.74 | — | — | |
| SCHEMBL15914861 | 0.72 | HDAC8 (0.36) | DAOHDAC8HDAC6AURKAAURKB | |
| SCHEMBL15364239 | 0.69 | — | — | |
| SCHEMBL16041245 | 0.66 | DAO (0.31) | DAOHDAC8HDAC6 | |
| SCHEMBL31522791 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173138-B2 | Ligands for pnicogen chelate complexes with a metal of subgroup VIII and use of the complexes as catalysts for hydroformylation, carbonylation, hydrocyanation or hydrogenation | BASF AKTIENGESELLSCHAFT (DE) | 2007-02-06 | — | — | US | disclosed |
| US-20040110960-A1 | Ligands for pnicogen chelate complexes with a metal of subgroup VIII and use of the complexes as catalysts for hydroformylation, carbonylation, hydrocyanation or hydrogenation | BASF AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110960-A1 | Ligands for pnicogen chelate complexes with a metal of subgroup VIII and use of the complexes as catalysts for hydroformylation, carbonylation, hydrocyanation or hydrogenation | OGG1, HPD, HPGD | DAO 3520/4885HDAC8 1015/4885HDAC6 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.